Predicting the Risk of Ovarian Cancer Recurrence Using Circulating Tumor DNA to Assess Residual Disease

Allegheny Health Network (AHN)

Status: Active, not recruiting

Conditions: Epithelial Ovarian Cancer

Treatments: Diagnostic Test: Altera Testing; Diagnostic Test: Signatera testing

Study type: Observational

Funder types: Other

Identifiers

NCT05212779

Signatera

Details and patient eligibility

About

Blood samples and Tumor tissue will be collected at certain timepoints and will be tested.

Full description

Blood samples will be tested by Natera to identify residual tumor DNA for genetic changes in the tumor to potentially improve prediction of long term prognosis and guide treatment options.

Enrollment: 45 estimated patients

Sex: Female

Ages: 18 to 95 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

Clinical diagnosis of epithelial ovarian cancer stage II-IV

Exclusion criteria

Insufficient tumor to perform Signatera testing; Inability to provide consent for the trial

Trial design

45 participants in 1 patient group

Females with Stage II-IV epithelial ovarian cancer

Description:

All patients, as participation requirements in this study, are required to have blood drawn at the completion of their adjuvant treatment. Blood sample should be collected within 6 weeks of receiving the last cycle of adjuvant chemotherapy. Other optional time points which will be encouraged but not required: 1. After debulking surgery 2. Serial draws every 3 months while on maintenance or surveillance.

Treatment:

Diagnostic Test: Altera Testing

Diagnostic Test: Signatera testing